Sellas Reports 57% Response Rate in TP53-Mutated AML With SLS009 Combination in Phase 2 Trial

Bitget2026/11/04 14:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sellas Life Sciences will present Phase 2 SLS009 combination results in relapsed or refractory acute myeloid leukemia on December 14, 2026.
SLS009 with azacitidine and venetoclax showed responses in patients whose prior venetoclax-based treatment failed, with encouraging survival versus historical outcomes.
The combination was well tolerated, with no meaningful added toxicity; benefits included patients with high-risk TP53-mutated or monocytic disease.
A separate Phase 2 trial in newly diagnosed patients continues enrollment, with initial topline data expected in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869955) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sellas Reports 57% Response Rate in TP53-Mutated AML With SLS009 Combination in Phase 2 Trial

You may also like

Crypto prices